Pembrolizumab, Ibrutinib and Rituximab in PCNSL

NCT04421560 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Primary Central Nervous System Lymphoma
Recurrent Cancer
Refractory Cancer
Relapsed Cancer

Interventions

DRUG: Ibrutinib
DRUG: Pembrolizumab
DRUG: Rituximab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]